OMIXCARE: OMICS technologies solved about 33% of the patients with heterogeneous rare neuro-developmental disorders and negative exome sequencing results and identified 13% additional candidate variants.
Front Cell Dev Biol
; 10: 1021785, 2022.
Article
in En
| MEDLINE
| ID: mdl-36393831
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Front Cell Dev Biol
Year:
2022
Document type:
Article
Affiliation country:
Country of publication: